Gene and Protein Information
class A G protein-coupled receptor
Species	TM	AA	Chromosomal Location	Gene Symbol	Gene Name	Reference
Human	7	487	3p25.3	HRH1	histamine receptor H1	18-19,27,50,70
Mouse	7	488	6 53.05 cM	Hrh1	histamine receptor H1	39
Rat	7	486	4q42	Hrh1	histamine receptor H 1	25

Previous and Unofficial Names

H1R | HH1R | Hisr

Database Links
Specialist databases
GPCRDB	hrh1_human (Hs), hrh1_mouse (Mm), hrh1_rat (Rn)
Other databases
Alphafold	P35367 (Hs)
ChEMBL Target	CHEMBL231 (Hs), CHEMBL4322 (Mm), CHEMBL4701 (Rn)
DrugBank Target	P35367 (Hs)
Ensembl Gene	ENSG00000196639 (Hs), ENSMUSG00000053004 (Mm), ENSRNOG00000007420 (Rn)
Entrez Gene	3269 (Hs), 15465 (Mm), 24448 (Rn)
Human Protein Atlas	ENSG00000196639 (Hs)
KEGG Gene	hsa:3269 (Hs), mmu:15465 (Mm), rno:24448 (Rn)
OMIM	600167 (Hs)
Pharos	P35367 (Hs)
RefSeq Nucleotide	NM_000861 (Hs), NM_008285 (Mm), NM_017018 (Rn)
RefSeq Protein	NP_000852 (Hs), NP_032311 (Mm), NP_058714 (Rn)
SynPHARM	2980 (in complex with doxepin) 9220 (in complex with [11C]doxepin)
UniProtKB	P35367 (Hs), P70174 (Mm), P31390 (Rn)
Wikipedia	HRH1 (Hs)

Selected 3D Structures
	Description:  Histamine H1 receptor in complex with antagonist PDB Id:  3RZE Ligand:  doxepin Resolution:  3.1Å Species:  Human References:  85

Natural/Endogenous Ligands
histamine

Download all structure-activity data for this target as a CSV file

Agonists
Key to terms and symbols	View all chemical structures	Click column headers to sort
Ligand Sp. Action Value Parameter Reference dimethylhistaprodifen Hs Full agonist 6.4 pKi 84 ⤷ pKi 6.4 [84] methylhistaprodifen Hs Full agonist 6.4 pKi 84 ⤷ pKi 6.4 (Ki 3.98x10-7 M) [84] ST-1006 Hs Agonist <6.0 pKi 77 ⤷ pKi <6.0 (Ki >1x10-6 M) [77] 2-(3-iodophenyl)histamine Hs Full agonist 5.8 pKi 84 ⤷ pKi 5.8 [84] 2-(3-bromophenyl)histamine Hs Full agonist 5.7 pKi 84 ⤷ pKi 5.7 [84] 2-(3-chlorophenyl)histamine Hs Full agonist 5.7 pKi 84 ⤷ pKi 5.7 [84] histaprodifen Hs Full agonist 5.7 pKi 53 ⤷ pKi 5.7 [53] 2-(2-thiazolyl)ethanamine Hs Partial agonist 5.3 pKi 84 ⤷ pKi 5.3 [84] histamine Hs Full agonist 4.7 – 5.9 pKi 8,70,80,84,93 ⤷ pKi 4.7 – 5.9 [8,70,80,84,93] UR-PG55B Hs Full agonist 5.2 pKi 93 ⤷ pKi 5.2 [93] UR-PG131A Hs Full agonist 4.7 pKi 93 ⤷ pKi 4.7 [93] UR-PG153 Hs Full agonist 4.7 pKi 93 ⤷ pKi 4.7 [93] oxo-arpromidine Hs Full agonist 4.5 pKi 93 ⤷ pKi 4.5 [93] UR-PG146 Hs Full agonist 4.4 pKi 93 ⤷ pKi 4.4 [93] 2-pyridylethylamine Hs Full agonist 3.7 pKi 80 ⤷ pKi 3.7 [80] vilazodone Hs Agonist 6.5 pIC50 35 ⤷ pIC50 6.5 (IC50 3.17x10-7 M) [35]

Antagonists
Key to terms and symbols	View all chemical structures	Click column headers to sort
Ligand Sp. Action Value Parameter Reference [11C]doxepin Hs Antagonist 9.0 pKd 41 ⤷ pKd 9.0 (Kd 1x10-9 M) [41] [3H]pyrilamine Hs Inverse agonist 8.4 – 9.1 pKd 19,70,83-84 ⤷ pKd 8.4 – 9.1 (Kd 4x10-9 – 7.9x10-10 M) [19,70,83-84] tripelennamine Hs Antagonist 8.0 pKd 34 ⤷ pKd 8.0 (Kd 1x10-8 M) [34] clemastine Hs Antagonist 10.3 pKi 3 ⤷ pKi 10.3 (Ki 4.9x10-11 M) [3] cyproheptadine Hs Antagonist 10.2 pKi 70 ⤷ pKi 10.2 [70] asenapine Hs Antagonist 9.8 pKi 83 ⤷ pKi 9.8 [83] doxepin Hs Antagonist 9.5 – 10.0 pKi 8 ⤷ pKi 9.5 – 10.0 [8] promethazine Hs Antagonist 9.6 pKi 29 ⤷ pKi 9.6 (Ki 2.4x10-10 M) [29] amitriptyline Hs Antagonist 9.3 pKi 29 ⤷ pKi 9.3 (Ki 5x10-10 M) [29] Description: Antagonism of [3H]mepyramine binding clozapine Hs Antagonist 8.8 – 9.6 pKi 8,47,83 ⤷ pKi 8.8 – 9.6 [8,47,83] zotepine Hs Antagonist 9.2 pKi 83 ⤷ pKi 9.2 [83] alimemazine Bt Antagonist 9.1 pKi 48 ⤷ pKi 9.1 (Ki 7.2x10-10 M) [48] Description: Inhibition of [3H]mepyramine binding to bovine brain membrane preparations in vitro. desloratadine Hs Antagonist 9.0 pKi 51 ⤷ pKi 9.0 (Ki 9.7x10-10 M) [51] olanzapine Hs Antagonist 8.7 – 9.2 pKi 47,83 ⤷ pKi 8.7 – 9.2 [47,83] azelastine Hs Antagonist 8.9 pKi 79 ⤷ pKi 8.9 (Ki 1.26x10-9 M) [79] mepyramine Hs Inverse agonist 8.7 – 9.0 pKi 8,80 ⤷ pKi 8.7 – 9.0 [8,80] triprolidine Hs Antagonist 8.5 – 9.0 pKi 8,70 ⤷ pKi 8.5 – 9.0 (Ki 3.16x10-9 – 1x10-9 M) [8,70] (-)-trans-H2-PAT Hs Antagonist 8.6 – 8.8 pKi 8 ⤷ pKi 8.6 – 8.8 [8] hydroxyzine Hs Antagonist 8.7 pKi 31 ⤷ pKi 8.7 (Ki 1.99x10-9 M) [31] ketotifen Hs Antagonist 8.6 pKi 49 ⤷ pKi 8.6 (Ki 2.5x10-9 M) [49] mizolastine Hs Antagonist 8.6 pKi 13 ⤷ pKi 8.6 (Ki 2.7x10-9 M) [13] Description: Radioligand displacement membrane binding assay using CHO cells expressing the human H1 receptor and [3H]pyrilamine as tracer. astemizole Hs Antagonist 8.5 pKi 78 ⤷ pKi 8.5 (Ki 3x10-9 M) [78] (±)-trans-H2-PAT Hs Antagonist 8.4 – 8.6 pKi 8 ⤷ pKi 8.4 – 8.6 [8] (R)-cetirizine Hs Inverse agonist 8.5 pKi 80 ⤷ pKi 8.5 [80] (+)-chlorpheniramine Hs Antagonist 8.3 – 8.6 pKi 8,70 ⤷ pKi 8.3 – 8.6 [8,70] thiothixene Hs Antagonist 8.4 pKi 47 ⤷ pKi 8.4 [47] dosulepin Hs Antagonist 8.4 pKi 87 ⤷ pKi 8.4 (Ki 4x10-9 M) [87] quetiapine Hs Antagonist 8.0 – 8.7 pKi 47,83 ⤷ pKi 8.0 – 8.7 [47,83] cyclizine Hs Antagonist 8.4 pKi 3 ⤷ pKi 8.4 (Ki 4.44x10-9 M) [3] chlorpromazine Hs Antagonist 8.2 pKi 47 ⤷ pKi 8.2 [47] loxapine Hs Antagonist 8.2 pKi 47 ⤷ pKi 8.2 [47] cetirizine Hs Inverse agonist 8.2 pKi 70 ⤷ pKi 8.2 [70] chlorpheniramine Hs Antagonist 8.1 pKi 79 ⤷ pKi 8.1 (Ki 7x10-9 M) [79] perphenazine Hs Antagonist 8.1 pKi 47 ⤷ pKi 8.1 [47] (±)-cis-H2-PAT Hs Antagonist 7.8 – 8.2 pKi 8 ⤷ pKi 8.1 – 8.2 [8] pKi 7.8 – 7.9 [8] fluspirilene Hs Antagonist 7.9 pKi 83 ⤷ pKi 7.9 [83] diphenhydramine Hs Antagonist 7.9 pKi 8 ⤷ pKi 7.9 [8] risperidone Hs Antagonist 7.6 – 7.8 pKi 47,83 ⤷ pKi 7.6 – 7.8 [47,83] thioridazine Hs Antagonist 7.7 pKi 47 ⤷ pKi 7.7 [47] fluphenazine Hs Antagonist 7.7 pKi 47 ⤷ pKi 7.7 [47] ziprasidone Hs Antagonist 7.4 – 7.8 pKi 47,83 ⤷ pKi 7.4 – 7.8 [47,83] fexofenadine Hs Antagonist 7.6 pKi 2 ⤷ pKi 7.6 (Ki 2.7x10-8 M) [2] aripiprazole Hs Antagonist 7.5 pKi 47 ⤷ pKi 7.5 [47] 9-OH-risperidone Hs Antagonist 7.5 pKi 83 ⤷ pKi 7.5 [83] AZD3778 Hs Antagonist 7.5 pKi 5 ⤷ pKi 7.5 (Ki 3.16x10-8 M) [5] Description: Assayed using the sodium salt of the compound (+)-trans-H2-PAT Hs Antagonist 7.4 – 7.5 pKi 8 ⤷ pKi 7.4 – 7.5 [8] loratadine Hs Antagonist 7.4 pKi 44 ⤷ pKi 7.4 (Ki 3.7x10-8 M) [44] terfenadine Hs Antagonist 7.4 pKi 2 ⤷ pKi 7.4 (Ki 4x10-8 M) [2] trifluoperazine Hs Antagonist 7.2 pKi 47 ⤷ pKi 7.2 [47] bilastine Hs Antagonist 7.2 pKi 14 ⤷ pKi 7.2 (Ki 6.4x10-8 M) [14] Description: Binding to human recombinant histamine H1 receptors (S)-dimetindene Hs Antagonist 7.2 pKi 11 ⤷ pKi 7.2 (Ki 6.9x10-8 M) [11] rupatadine Cp Antagonist 7.0 pKi 64 ⤷ pKi 7.0 (Ki 1x10-7 M) [64] Description: [3H]-pyrilamine binding to guinea pig cerebellum membranes. sertindole Hs Antagonist 6.9 pKi 47,83 ⤷ pKi 6.9 [47,83] (+)-cis-H2-PAT Hs Antagonist 6.9 pKi 8 ⤷ pKi 6.9 [8] (S)-cetirizine Hs Inverse agonist 6.7 pKi 80 ⤷ pKi 6.7 [80] BU-E 47 Hs Antagonist 6.6 pKi 84 ⤷ pKi 6.6 [84] (-)-chlorpheniramine Hs Antagonist 6.4 – 6.7 pKi 8 ⤷ pKi 6.4 – 6.7 [8] arpromidine Hs Antagonist 6.5 pKi 84,93 ⤷ pKi 6.5 [84,93] pimozide Hs Antagonist 6.2 pKi 47 ⤷ pKi 6.2 [47] JNJ-39758979 Hs Antagonist <6.0 pKi 77 ⤷ pKi <6.0 (Ki >1x10-6 M) [77] haloperidol Hs Antagonist 5.7 – 6.1 pKi 47,83 ⤷ pKi 5.7 – 6.1 [47,83] ABT-239 Hs Inverse agonist 5.8 pKi 23 ⤷ pKi 5.8 [23] pitolisant Hs Antagonist 5.8 pKi 77 ⤷ pKi 5.8 [77] molindone Hs Antagonist 5.7 pKi 47 ⤷ pKi 5.7 [47] pipamperone Hs Antagonist 5.6 pKi 83 ⤷ pKi 5.6 [83] A-349821 Hs Inverse agonist 5.6 pKi 22 ⤷ pKi 5.6 [22] clobenpropit Hs Antagonist 5.6 pKi 24 ⤷ pKi 5.6 [24] A-317920 Hs Antagonist 5.4 pKi 22,24 ⤷ pKi 5.4 [22,24] impromidine Hs Antagonist 5.2 pKi 93 ⤷ pKi 5.2 [93] ciproxifan Hs Antagonist <5.0 pKi 77 ⤷ pKi <5.0 (Ki >1x10-5 M) [77] MK-0249 Hs Antagonist <5.0 pKi 77 ⤷ pKi <5.0 (Ki >1x10-5 M) [77] conessine Hs Antagonist <5.0 pKi 77 ⤷ pKi <5.0 (Ki >1x10-5 M) [77] INCB-38579 Hs Antagonist <5.0 pKi 77 ⤷ pKi <5.0 (Ki >1x10-5 M) [77] rupatadine Hs Antagonist 8.4 pIC50 73 ⤷ pIC50 8.4 (IC50 3.9x10-9 M) [73] epinastine Hs Antagonist 7.6 pIC50 37 ⤷ pIC50 7.6 (IC50 2.5x10-8 M) [37] Description: Antagonism of 5 nM [3H]mepyramine binding in an intact cell assay using U373 MG astrocytoma cells. tripelennamine Hs Antagonist 7.4 pIC50 34 ⤷ pIC50 7.4 (IC50 3.98x10-8 M) [34] mizolastine Cp Antagonist 7.3 pIC50 6 ⤷ pIC50 7.3 (IC50 4.7x10-8 M) [6] Description: Inhibition of [3H]pyrilamine binding to histamine H1 receptors in guinea pig cerebellar membranes and sections. [11C]pyrilamine Hs Inverse agonist - - ⤷
View species-specific antagonist tables
Antagonist Comments
Astemizole is highly selective for the histamine H1 receptor over the H2 receptor.

Immunopharmacology Comments

The H1 receptor was the first of the family to be targeted for clinical use, with antagonists (anti-histamines) developed that are still used widely to treat allergic inflammation such as rhinitis, allergic conjunctivitis, urticaria and even anaphylaxis.

Cell Type Associations

Immuno Cell Type:  Granulocytes Cell Ontology Term:   eosinophil (CL:0000771) Comment:  Eosinophils express all four histamine receptor subtypes. References:  30,65

Immuno Cell Type:  Mast cells Cell Ontology Term:   mast cell (CL:0000097) Comment:  In humans, mast cells express H1R, H2R and H4R. References:  28

Immuno Process Associations

Immuno Process:  Inflammation GO Annotations:  Associated to 2 GO processes GO:0006954 inflammatory response TAS click arrow to show/hide IEA associations GO:0048245 eosinophil chemotaxis IEA

Immuno Process:  Chemotaxis & migration GO Annotations:  Associated to 1 GO processes, IEA only click arrow to show/hide IEA associations GO:0048245 eosinophil chemotaxis IEA

Primary Transduction Mechanisms
Transducer	Effector/Response
Gq/G11 family	Adenylyl cyclase stimulation
Comments:  Stimulation of cAMP accumulation is via Gβγ subunits of Gq [59].
References:  59

Secondary Transduction Mechanisms
Transducer	Effector/Response
Gq/G11 family	Phospholipase C stimulation
References:  52

Tissue Distribution
Cranial arteries. Species:  Human Technique:  RT-PCR. References:  43
Brain: cerebrum. Heart: myocardium (ventricle > atrium). Species:  Human Technique:  Northern and Western blotting. References:  63
Brain. Species:  Human Technique:  Positron emission tomography (PET). References:  69
Myometrium. Species:  Human Technique:  Radioligand binding. References:  32
Gastrointestinal tract. Species:  Human Technique:  qRT-PCR and immunohistochemistry. References:  81
Uterine horns. Species:  Mouse Technique:  Radioligand binding. References:  33
Mast cells. Species:  Mouse Technique:  RT-PCR. References:  38
Embryonic brain and spinal cord. Species:  Rat Technique:  in situ hybridization, RT-PCR and Northern blotting. References:  46
Sympathetic preganglionic neurons in the spinal cord. Species:  Rat Technique:  RT-PCR. References:  91
Cochlea. Species:  Rat Technique:  RT-PCR. References:  4
Brain: cerebrum. Heart: myocardium (atrium and ventricle). Species:  Rat Technique:  Northern and Western blotting. References:  63

Expression Datasets
Show »« Hide Log average relative transcript abundance in mouse tissues measured by qPCR from Regard, J.B., Sato, I.T., and Coughlin, S.R. (2008). Anatomical profiling of G protein-coupled receptor expression. Cell, 135(3): 561-71. [PMID:18984166] [Raw data: website] There should be a chart of expression data here, you may need to enable JavaScript!

Functional Assays
Measurement of IP levels in COS-7 cells transfected with the human H1 receptor. Species:  Human Tissue:  COS-7 cells. Response measured:  Stimulation of IP formation. References:  18
Measurement of IP levels in CHO cells transfected with the human H1 receptor. Species:  Human Tissue:  CHO cells. Response measured:  Stimulation of IP formation. References:  8
Measurement of AC activity in baculovirus-infected Sf9 insect cells expressing the human H1 receptor. Species:  Human Tissue:  Sf9 cells. Response measured:  Stimulation of AC activity. References:  93
Measurement of cAMP levels in CHO cells transfected with the human H1 receptor. Species:  Human Tissue:  CHO cells. Response measured:  Stimulation of cAMP accumulation. References:  59
Measurement of PLC activity and Ca2+ mobilisation in cultured ciliary muscle cells endogenously expressing the H1 receptor. Species:  Human Tissue:  Cultured ciliary muscle cells. Response measured:  Activation of PLC and mobilisation of both intracellular and extracellular Ca2+. References:  57
Measurement of IP levels in cultured human endothelial cells endogenously expressing the H1 receptor. Species:  Human Tissue:  Cultured umbilical vein endothelial cells. Response measured:  Stimulation of IP formation. References:  54
Measurement of mitogenesis in human astrocytoma U373 MG cells endogenously expressing the H1 receptor. Species:  Human Tissue:  Astrocytoma U373 MG cells. Response measured:  Cell proliferation via PKC and MAPK. References:  36
Measurement of Ca2+ levels as well as ERK1/2 and PKC activity in human primary epithelial cells and the NCI-H292 cell line, both endogenously expressing the H1 receptor. Species:  Human Tissue:  Primary epithelial cells and the NCI-H292 cell line. Response measured:  Elevation of Ca2+ levels and activation of PKC and ERK1/2. References:  62
Measurement of IP, DAG and Ca2+ levels in human HeLa carcinoma cells endogenously expressing the H1 receptor. Species:  Human Tissue:  HeLa carcinoma cells. Response measured:  Formation of IP and DAG and a rise in Ca2+ levels. References:  89

Physiological Functions
Modulation of neuronal firing. Species:  Rat Tissue:  Dorsal raphe nucleus. References:  10
Relaxation of smooth muscle (via an endothelial H1 receptor). Species:  Human Tissue:  Cranial arteries. References:  43
Contraction of smooth muscle. Species:  Human Tissue:  Arterial rings. References:  17
Modulation of adrenergic neurotransmission. Species:  Rat Tissue:  Vas deferens. References:  90
Bronchoconstriction. Species:  Human Tissue:  In vivo. References:  12,15,20,55,74,88
Inhibition of locomotor behaviour. Species:  Rat Tissue:  In vivo. References:  1
Modulation of feeding behaviour. Species:  Rat Tissue:  In vivo. References:  26
Modulation of feeding behaviour. Species:  Mouse Tissue:  In vivo. References:  60-61,71-72
Hypernociception. Species:  Rat Tissue:  In vivo. References:  56
Endothelium-dependent vasodilation. Species:  Rat Tissue:  Mesenteric vascular beds. References:  45
Role in the stimulation of skin blood flow during whole body heating. Species:  Human Tissue:  In vivo. References:  92
Stimulation of the nitric oxide signalling system. Species:  Rat Tissue:  Submandibular gland. References:  9
Increased vascular permeability. Species:  Mouse Tissue:  In vivo. References:  7,75
Contraction of smooth muscle. Species:  Human Tissue:  Isolated uterine strips. References:  58
Contraction of smooth muscle. Species:  Rat Tissue:  Isolated stomach fundus. References:  21
Increase in substantia nigra pars reticulata (SNr) inhibitory projection neuron firing frequency (via cell depolarisation). The balance between the effect of H1 and H2 receptors and the opposing effect of H3 receptors may contribute to movement control. Species:  Mouse Tissue:  Coronal midbrain slices. References:  96
Depolarisation. Species:  Rat Tissue:  Sympathetic preganglionic neurons. References:  91
Regulation of cytokine production. Species:  Mouse Tissue:  CD4+ and CD8+ T cells. References:  86
Prostacyclin formation. Species:  Human Tissue:  Pulmonary artery. References:  82

Physiological Consequences of Altering Gene Expression
H1 receptor knockout mice develop normally, but exhibit impaired locomotor activity and exploratory behavior. Species:  Mouse Tissue:  Technique:  Gene targeting in embryonic stem cells. References:  40,95
H1 receptor knockout mice subjected to social isolation after weaning exhibit similar levels of locomotor activity to socially reared H1 receptor knockout mice. This is in contrast to wild-type mice, where there is a significant decrease in locomotor activity in socially isolated WT mice compared with socially reared WT mice. It is suggested that blockade of H1 receptors by atypical antipsychotics attenuates social isolation-induced behavioral changes. Species:  Mouse Tissue:  Technique:  Gene targeting in embryonic stem cells. References:  16
H1 receptor knockout mice exhibit decreased exploratory activity, reduced levels of anxiety and aggression, a decrease in nociceptive response and an increased 5-HT turnover rate in the cerebral cortex and hippocampus. Species:  Mouse Tissue:  Technique:  Gene targeting in embryonic stem cells. References:  94
H1 receptor knockout mice exhibit a significant decrease in nociception compared to wild-type mice. Species:  Mouse Tissue:  Technique:  Gene targeting in embryonic stem cells. References:  67
H1 knockout mice exhibit enhancement of morphine-induced antinociception. Species:  Mouse Tissue:  Technique:  Gene targeting in embryonic stem cells. References:  66
H1 receptor knockout mice do not exhibit an increase in respiratory frequency upon elevation of body temperature, as observed in wild-type mice. Species:  Mouse Tissue:  Technique:  Gene targeting in embryonic stem cells. References:  42
H1 receptor knockout mice exhibit a reduction in the effect of neurotensin on the supression of food intake. Species:  Mouse Tissue:  Technique:  Gene targeting in embryonic stem cells. References:  76
H1 receptor knockout mice do not exhibit an increase in vascular permeability of the conjunctiva, as observed in wild-type mice. Species:  Mouse Tissue:  Technique:  Gene targeting in embryonic stem cells. References:  75
CD4+ T cells from H1 receptor knockout mice exhibit a decrease in the release of Il-2 and Il-10, and an increase in the release of IL-4. CD8+ T cells from H1 receptor knockout mice also exhibit a decrease in the release of Il-2 and Il-10, as well as an increase in the release of IFN-γ. Species:  Mouse Tissue:  Technique:  Gene targeting in embryonic stem cells. References:  86
H1 receptor knockout mice exhibit enhanced antinociception by administration of orexin-A, compared to wild-type mice following administration of orexin-A. Species:  Mouse Tissue:  Technique:  Gene targeting in embryonic stem cells. References:  68

Phenotypes, Alleles and Disease Models

Mouse data from MGI

Show »« Hide Allele Composition & genetic background Accession Phenotype Id Phenotype Reference Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn involves: 129P2/OlaHsd * C57BL/6 MGI:107619  MP:0004924 abnormal behavior PMID: 8917588  Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn involves: 129P2/OlaHsd * C57BL/6 MGI:107619  MP:0001502 abnormal circadian rhythm PMID: 8917588  Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn B6.129P2-Hrh1 MGI:107619  MP:0003638 abnormal response/metabolism to endogenous compounds PMID: 15331534  Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn involves: 129P2/OlaHsd * C57BL/6 MGI:107619  MP:0005093 decreased B cell proliferation PMID: 9989982  Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn B6.129P2-Hrh1 MGI:107619  MP:0001262 decreased body weight PMID: 15331534  Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn B6.129P2-Hrh1 MGI:107619  MP:0002727 decreased circulating insulin level PMID: 15331534  Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn B6.129P2-Hrh1 MGI:107619  MP:0003910 decreased eating behavior PMID: 15331534  Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn involves: 129P2/OlaHsd * C57BL/6 MGI:107619  MP:0001417 decreased exploration in new environment PMID: 8917588  Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn involves: 129P2/OlaHsd * C57BL/6 MGI:107619  MP:0008498 decreased IgG3 level PMID: